Evaluation of a Novel Prefilled Syringe Concept for Ophthalmic Applications: A Formative Human Factors Study

References

1. 1.↵
   1. Freund K. B.,
   2. Haller J. A.,
   3. Jumper J. M.,
   4. Liebmann J. M.,
   5. McCannel C. A.,
   6. Mieler W. F.,
   7. Ta C. N.,
   8. Williams G. A.

   1. Avery R. L.,
   2. Bakri S. J.,
   3. Blumenkranz M. S.,
   4. Brucker A. J.,
   5. Cunningham E. T.,
   6. D'Amico D. J.,
   7. Dugel P. U.,
   8. Flynn H. W.

   Jr; Freund K. B., Haller J. A., Jumper J. M., Liebmann J. M., McCannel C. A., Mieler W. F., Ta C. N., Williams G. A. Intravitreal Injection Technique and Monitoring: Updated Guidelines of an Expert Panel. Retina 2014, 34 (Supplement 12), S1–S18.

   OpenUrlGoogle Scholar
2. 2.↵
   1. Grzybowski A.,
   2. Told R.,
   3. Sacu S.,
   4. Bandello F.,
   5. Moisseiev E.,
   6. Loewenstein A.,
   7. Schmidt-Erfurth U

   , on behalf of the Euretina Board. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica 2018, 239 (4), 181–193.

   OpenUrlPubMedGoogle Scholar
3. 3.↵
   1. Hartman R. R.,
   2. Kompella U. B.

   Intravitreal, Subretinal, and Suprachoroidal Injections: Evolution of Microneedles for Drug Delivery. J. Ocul. Pharmacol. Ther. 2018, 34 (1-2), 141–153.

   OpenUrlGoogle Scholar
4. 4.↵
   1. Shikari H.,
   2. Samant P.

   Intravitreal Injections: A Review of Pharmacological Agents and Techniques. J. Clin. Ophthalmol. Res. 2016, 4 (1), 51–59.

   OpenUrlGoogle Scholar
5. 5.↵
   1. Stewart M. W.

   The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology. Mayo Clin. Proc. 2012, 87 (1), 77–88.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
6. 6.↵
   1. Mathalone N.,
   2. Arodi-Golan A.,
   3. Sar S.,
   4. Wolfson Y.,
   5. Shalem M.,
   6. Lavi I.,
   7. Geyer O.

   Sustained Elevation of Intraocular Pressure after Intravitreal Injections of Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration. Graefe’s. Arch. Clin. Exp. Ophthalmol. 2012, 250 (10), 1435–1440.

   OpenUrlCrossRefPubMedGoogle Scholar
7. 7.↵
   1. Ghasemi Falavarjani K.,
   2. Nguyen Q. D.

   Adverse Events and Complications Associated with Intravitreal Injection of anti-VEGF Agents: A Review of Literature. Eye 2013, 27 (7), 787–794.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
8. 8.↵
   1. Baudin F.,
   2. Benzenine E.,
   3. Mariet A.-S.,
   4. Bron A. M.,
   5. Daien V.,
   6. Korobelnik J. F.,
   7. Quantin C.,
   8. Creuzot-Garcher C.

   Association of Acute Endophthalmitis with Intravitreal Injections of Corticosteroids or anti–Vascular Growth Factor Agents in a Nationwide Study in France. JAMA Ophthalmol. 2018, 136 (12), 1352–1358.

   OpenUrlGoogle Scholar
9. 9.↵
   1. VanderBeek B. L.,
   2. Bonaffini S. G.,
   3. Ma L.

   Association of Compounded Bevacizumab with Postinjection Endophthalmitis. JAMA Ophthalmol. 2015, 133 (10), 1159–1164.

   OpenUrlGoogle Scholar
10. 10.↵
    1. Sheyman A. T.,
    2. Cohen B. Z.,
    3. Friedman A. H.,
    4. Ackert J. M.

    An Outbreak of Fungal Endophthalmitis after Intravitreal Injection of Compounded Combined Bevacizumab and Triamcinolone. JAMA Ophthalmol. 2013, 131 (7), 864–869.

    OpenUrlGoogle Scholar
11. 11.↵
    1. Edison L. S.,
    2. Dishman H. O.,
    3. Tobin-D’Angelo M. J.,
    4. Allen C. R.,
    5. Guh A. Y.,
    6. Drenzek C. L.

    Endophthalmitis Outbreak Associated with Repackaged Bevacizumab. Emerging Infect. Dis. 2015, 21 (1), 171–173.

    OpenUrlGoogle Scholar
12. 12.↵
    1. Goldberg R. A.,
    2. Shah C. P.,
    3. Wiegand T. W.,
    4. Heier J. S.

    Noninfectious Inflammation after Intravitreal Injection of Aflibercept: Clinical Characteristics and Visual Outcomes. Am. J. Ophthalmol. 2014, 158 (4), 733–737.e1.

    OpenUrlGoogle Scholar
13. 13.↵
    1. Freund K. B.,
    2. Laud K.,
    3. Eandi C. M.,
    4. Spaide R. F.

    Silicone Oil Droplets following Intravitreal Injection. Retina 2006, 26 (6), 701–703.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
14. 14.↵
    1. Avery R. L.,
    2. Castellarin A. A.,
    3. Dhoot D. S.,
    4. Pieramici D. J.,
    5. Nasir M. A.,
    6. Steinle N. C.,
    7. Avery L. P.,
    8. Gordon G. M.

    Large Silicone Droplets after Intravitreal Bevacizumab (Avastin). Retin. Cases Brief Rep. 2019, 13 (2), 130–134.

    OpenUrlGoogle Scholar
15. 15.↵
    1. Bakri S. J.,
    2. Ekdawi N. S.

    Intravitreal Silicone Oil Droplets after Intravitreal Drug Injections. Retina 2008, 28 (7), 996–1001.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
16. 16.↵
    1. Khurana R. N.,
    2. Chang L. K.,
    3. Porco T. C.

    Incidence of Presumed Silicone Oil Droplets in the Vitreous Cavity after Intravitreal Bevacizumab Injection with Insulin Syringes. JAMA Ophthalmol. 2017, 135 (7), 800–803.

    OpenUrlGoogle Scholar
17. 17.↵
    1. Liu L.,
    2. Ammar D. A.,
    3. Ross L. A.,
    4. Mandava N.,
    5. Kahook M. Y.,
    6. Carpenter J. F.

    Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-Term Storage and Product Mishandling. Invest. Ophthalmol. Vis. Sci. 2011, 52 (2), 1023–1034.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
18. 18.↵
    1. Kocabora M. S.,
    2. Ozbilen K. T.,
    3. Serefoglu K.

    Intravitreal Silicone Oil Droplets following Pegaptanib Injection. Acta Ophthalmol. 2010, 88 (2), e44–e45.

    OpenUrlPubMedGoogle Scholar
19. 19.↵
    1. Melo G. B.,
    2. Dias Junior C D. S.,
    3. Carvalho M. R.,
    4. Cardoso A. L.,
    5. Morais F. B.,
    6. Figueira A.,
    7. Lima Filho A.,
    8. Emerson G. G.,
    9. Maia M.

    Release of Silicone Oil Droplets from Syringes. Int. J. Retina Vitr. 2019, 5 (1),

    Google Scholar
20. 20.↵
    1. Olea J. L.,
    2. Gómez-Resa M.,
    3. Cervera-Peris M. M.,
    4. Aragón J. A.

    Silicone Oil Droplets in Repackaged anti–Vascular Endothelial Growth Factors for Intravitreal Injections: In Search of the Main Source of Contamination. Eur. J. Ophthalmol. 2020, 30 (4), 774–779.

    OpenUrlPubMedGoogle Scholar
21. 21.↵
    1. Schargus M.,
    2. Werner B. P.,
    3. Geerling G.,
    4. Winter G.

    Contamination of anti-VEGF Drugs for Intravitreal Injection: How Do Repackaging and Newly Developed Syringes Affect the Amount of Silicone Oil Droplets and Protein Aggregates?. Retina 2018, 38 (10), 2088–2095.

    OpenUrlGoogle Scholar
22. 22.↵
    1. Tayyab H.,
    2. Khan A. A.,
    3. Sadiq M. A. A.,
    4. Jahangir S.,
    5. Sarwar S.

    Silicone Oil Droplets in Vitreous after Intravitreal Bevacizumab Injection. Pak. J. Ophthalmol. 2018 35 (2), 144–148.

    OpenUrlGoogle Scholar
23. 23.↵
    1. Yu J. H.,
    2. Gallemore E.,
    3. Kim J. K.,
    4. Patel R.,
    5. Calderon J.,
    6. Gallemore R. P.

    Silicone Oil Droplets following Intravitreal Bevacizumab Injections. Am. J. Ophthalmol. Case Rep. 2018, 10, 142–144.

    OpenUrlPubMedGoogle Scholar
24. 24.↵
    1. Scott I. U.,
    2. Oden N. L.,
    3. VanVeldhuisen P. C.,
    4. Ip M. S.,
    5. Blodi B. A.,
    6. Antoszyk A. N.

    SCORE Study Report 7: Incidence of Intravitreal Silicone Oil Droplets Associated with Staked-on vs Luer Cone Syringe Design. Am. J. Ophthalmol. 2009, 148 (5), 725–732.e7.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
25. 25.↵
    1. Good T. J.,
    2. Kimura A. E.,
    3. Mandava N.,
    4. Kahook M. Y.

    Sustained Elevation of Intraocular Pressure after Intravitreal Injections of anti-VEGF Agents. Br. J. Ophthalmol. 2011, 95 (8), 1111–1114.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
26. 26.↵
    1. Antoszyk A. N.,
    2. Baker C.,
    3. Calzada J.,
    4. Cummings H.,
    5. So J.,
    6. Quezada-Ruiz C.,
    7. Haskova Z.

    Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals. PDA J. Pharm. Sci. Technol. 2018, 72 (4), 411–419.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
27. 27.↵
    1. Souied E.,
    2. Nghiem-Buffet S.,
    3. Leteneux C.,
    4. Bayer S.,
    5. Derveloy A.,
    6. Sagkriotis A.,
    7. Becker G.,
    8. Cohen S.-Y.

    Ranibizumab Prefilled Syringes: Benefits of Reduced Syringe Preparation Times and Less Complex Preparation Procedures. Eur. J. Ophthalmol. 2015, 25 (6), 529–534.

    OpenUrlGoogle Scholar
28. 28.↵
    1. Subhi Y.,
    2. Kjer B.,
    3. Munch I. C.

    Prefilled Syringes for Intravitreal Injection Reduce Preparation Time. Dan. Med. J. 2016, 63 (4), A5214.

    OpenUrlGoogle Scholar
29. 29.↵
    1. Michaud J.-E.,
    2. Sigg J.,
    3. Boado L.,
    4. Momm J.,
    5. Weber C.,
    6. Alete D.,
    7. Peregi E.,
    8. Picci M.

    Ranibizumab Pre-Filled Syringe Approved in the European Union: Innovation to Improve Dose Accuracy, Reduce Potential Infection Risk, and Offer More Efficient Treatment Administration. Invest. Ophthalmol. Visual Sci. 2014, 55 (13), 1949.

    OpenUrlGoogle Scholar
30. 30.↵
    1. Storey P. P.,
    2. Tauqeer Z.,
    3. Yonekawa Y.,
    4. Todorich B.,
    5. Wolfe J. D.,
    6. Shah S. P.,
    7. Shah A. R.,
    8. Koto T.,
    9. Abbey A. M.,
    10. Morizane Y.,
    11. Sharma P.,
    12. Wood E. H.,
    13. Morizane-Hosokawa M.,
    14. Pendri P.,
    15. Pancholy M.,
    16. Harkey S.,
    17. Jeng-Miller K. W.,
    18. Obeid A.,
    19. Borkar D. S.,
    20. Chen E.,
    21. Williams P.,
    22. Okada A. A.,
    23. Inoue M.,
    24. Shiraga F.,
    25. Hirakata A.,
    26. Shah C. P.,
    27. Prenner J.,
    28. Garg S.

    The Impact of Prefilled Syringes on Endophthalmitis following Intravitreal Injection of Ranibizumab. Am. J. Ophthalmol. 2019, 199, 200–208.

    OpenUrlGoogle Scholar
31. 31.↵
    1. Loewenstein I.,
    2. Goldstein M.,
    3. Moisseiev J.,
    4. Moisseiev E.

    Accuracy and Precision of Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents in Real Life: What is Actually in the Syringe?. Retina 2019, 39 (7), 1385–1391.

    OpenUrlGoogle Scholar
32. 32.↵
    1. Buerke B.,
    2. Puesken M.,
    3. Mellmann A.,
    4. Seifarth H.,
    5. Heindel W.,
    6. Wessling J.

    Microbiologic Contamination and Time Efficiency of Use of Automatic MDCT Injectors with Prefilled Syringes: Results of a Clinical Investigation. Am. J. Roentgenol. 2010, 194 (2), 299–303.

    OpenUrlCrossRefPubMedGoogle Scholar
33. 33.↵
    1. Moisseiev E.,
    2. Rudell J.,
    3. Tieu E. V.,
    4. Yiu G.

    Effect of Syringe Design on the Accuracy and Precision of Intravitreal Injections of anti-VEGF Agents. Curr. Eye Res. 2017, 42 (7), 1059–1063.

    OpenUrlGoogle Scholar
34. 34.↵
    1. Sassalos T. M.,
    2. Paulus Y. M.

    Prefilled Syringes for Intravitreal Drug Delivery. Clin. Ophthalmol. 2019, 13, 701–706.

    OpenUrlGoogle Scholar
35. 35.↵
    1. Makwana S.,
    2. Basu B.,
    3. Makasana Y.,
    4. Dharamsi A.

    Prefilled Syringes: An Innovation in Parenteral Packaging. Int. J. Pharm. Invest. 2011, 1 (4), 200–206.

    OpenUrlGoogle Scholar
36. 36.↵
    U.S. Food and Drug Administration, Guidance for Industry and Food and Drug Administration Staff: Applying Human Factors and Usability Engineering to Medical Devices. Center for Devices and Radiological Health: Rockville, MD, 2016.

    Google Scholar
37. 37.↵
    LUCENTIS (ranibizumab). [package insert]. South San Francisco, CA; Genentech, Inc, 2018.

    Google Scholar
38. 38.↵
    1. Sukgen E. A.,
    2. Gunay M.,
    3. Kocluk Y.

    Occurrence of Intraocular Air Bubbles during Intravitreal Injections for Retinopathy of Prematurity. Int. Ophthalmol. 2017, 37 (1), 215–219.

    OpenUrlGoogle Scholar
39. 39.↵
    1. Lim W. S.,
    2. Sikandar M.,
    3. Jackson H.

    Air Entry into the Anterior Chamber Post Intravitreal Injection of Eylea. BMJ Case Reports. 2016, 2016, bcr2016216247.

    OpenUrlGoogle Scholar
40. 40.↵
    1. Badkar A.,
    2. Wolf A.,
    3. Bohack L.,
    4. Kolhe P.

    Development of Biotechnology Products in Pre-Filled Syringes: Technical Considerations and Approaches. AAPS PharmSciTech 2011, 12 (2), 564–572.

    OpenUrlPubMedGoogle Scholar
41. 41.↵
    1. Bee J. S.,
    2. Frey V. V.,
    3. Javed U.,
    4. Chung J.,
    5. Corcoran M. L.,
    6. Roussel P. S.,
    7. Krause S. O.,
    8. Cash P. W.,
    9. Bishop S. M.,
    10. Dimitrova M. N.

    Characterization of the Initial Level and Migration of Silicone Oil Lubricant in Empty Prefilled Syringes for Biologics Using Infrared Spectroscopy. PDA J. Pharm. Sci. Technol. 2014, 68 (5), 494–503.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
42. 42.↵
    1. Funke S.,
    2. Matilainen J.,
    3. Nalenz H.,
    4. Bechtold-Peters K.,
    5. Mahler H.-C.,
    6. Friess W.

    Silicone Migration from Baked-on Silicone Layers. Particle Characterization in Placebo and Protein Solutions. J. Pharm. Sci. 2016, 105 (12), 3520–3531.

    OpenUrlGoogle Scholar
43. 43.↵
    1. Yoshino K.,
    2. Nakamura K.,
    3. Yamashita A.,
    4. Abe Y.,
    5. Iwasaki K.,
    6. Kanazawa Y.,
    7. Funatsu K.,
    8. Yoshimoto T.,
    9. Suzuki S.

    Functional Evaluation and Characterization of a Newly Developed Silicone Oil-Free Prefillable Syringe System. J. Pharm. Sci. 2014, 103 (5), 1520–1528.

    OpenUrlPubMedGoogle Scholar
44. 44.↵
    1. Liebmann-Vinson A.

    Physics of Friction Applied to Medical Devices. In: Microstructure and Microtribology of Polymer Surfaces. Vol 741. ACS Symposium Series. American Chemical Society; 1999:474–494. doi:10.1021/bk-2000-0741.ch030.

    Google Scholar
45. 45.↵
    1. Lanzetta P.,
    2. Holz F.,
    3. Monés J.,
    4. Querques G.,
    5. Stanga P.,
    6. Veritti D.,
    7. Barbone F.,
    8. Brusaferro S.,
    9. Isola M.

    Intravitreal Injections: A Healthcare Failure Modes and Effects Analysis. Ophthalmologica 2013, 230 (3), 151–164.

    OpenUrlGoogle Scholar
46. 46.↵
    1. Shetty G.,
    2. Zeiss B.

    Microlitre Dosing with Prefillable Syringes—When Does a Device Make Sense? ONdrugDelivery Magazine 2019, (97), 28–31.

    Google Scholar
47. 47.↵
    1. Krayukhina E.,
    2. Tsumoto K.,
    3. Uchiyama S.,
    4. Fukui K.

    Effects of Syringe Material and Silicone Oil Lubrication on the Stability of Pharmaceutical Proteins. J. Pharm. Sci. 2015, 104 (2), 527–535.

    OpenUrlPubMedGoogle Scholar
48. 48.↵
    1. Foglia P.,
    2. Prete C. A.,
    3. Zanda M.

    An Inspection System for Pharmaceutical Glass Tubes. WSEAS Transactions on Systems 2015, 14, 123–136.

    OpenUrlGoogle Scholar